Vaxil Bio Therapeutics is an Israel-based immuno-oncology biotechnology company specializing in cancer and infectious diseases. It conducts research and development of medical solutions for its studied illnesses. Its lead product, IMMUCIN, is for immunotherapy purposes and has been given orphan drug status from both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
In 2020, the company utilized its VaxHit bioinformatics platform to create a vaccine candidate for COVID-19 using signal peptide technology. The candidate's design has been successful in testing a tuberculosis vaccine.
Vaxil Announces the Identification of a Potential Corona Virus Vaccine and Provides an Update in the Previously Announced Debt Financing
Vaxil Bio Ltd.
February 13, 2020
Vaxil Bio : COMMENCES PRECLINICAL COVID-19 VACCINE TRIAL AND FILES AN ADDITIONAL COVID-19 PATENT | MarketScreener
March 27, 2020
Documentaries, videos and podcasts
VAXIL Introduction - Cancer Immunotherapy
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.
- Cluster: BiotechnologyA cluster of topics related to biotechnology.